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Vascular disease is still the leading cause of morbidity and mortality in the Western
world, and the primary cause of myocardial infarction, stroke, and ischemia. The biology
of vascular disease is complex and still poorly understood in terms of causes and
consequences. Vascular function is determined by structural and functional properties of
the arterial vascular wall. Arterial stiffness, that is a pathological alteration of the vascular
wall, ultimately results in target-organ damage and increasedmortality. Arterial remodeling
is accelerated under conditions that adversely affect the balance between arterial function
and structure such as hypertension, atherosclerosis, diabetes mellitus, chronic kidney
disease, inflammatory disease, lifestyle aspects (smoking), drugs (vitamin K antagonists),
and genetic abnormalities [e.g., pseudoxanthoma elasticum (PXE), Marfan’s disease]. The
aim of this review is to provide an overview of the complex mechanisms and different
factors that underlie arterial remodeling, learning from single gene defect diseases like
PXE, and PXE-like, Marfan’s disease and Keutel syndrome in vascular remodeling.
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INTRODUCTION
Arterial remodeling refers to the myriad of structural and
functional changes of the vascular wall that occur in response
to disease, injury, or aging. Although arterial remodeling can
be regarded as a mechanism that naturally occurs with aging,
early arterial remodeling is associated with significant hemo-
dynamic changes and cardiovascular morbidity and mortality.
Arterial remodeling is set into motion by a variety of complex
pathophysiological mechanisms that are closely interrelated, and
that influence both the cellular and non-cellular components of
the vascular wall. Mechanisms involved in arterial remodeling
include fibrosis, hyperplasia of the arterial intima and media,
changes in vascular collagen and elastin, endothelial dysfunction,
and arterial calcification. Migration and proliferation of vascu-
lar smooth muscle cells (VSMCs) contribute to thickening of the
arterial intima. Differentiation of VSMCs from their contractile
to a secretory or osteogenic phenotype may lead to increased
vascular tone, and promotes extracellular matrix (ECM) cal-
cification. Additionally, alterations in the activity of vitamin
K-dependent proteins may affect the progression of vascular
remodeling, including the induction of calcification. Because of
this complexity, it is difficult to study to what extent a sin-
gle mechanism contributes to arterial remodeling. Monogenetic
diseases such as pseudoxanthoma elasticum (PXE), PXE-like syn-
drome, Marfan’s syndrome or Keutel syndrome are characterized
by a clinical phenotype that is similar to that of arterial remod-
eling, but are caused by a specific defect that affects only one
or several pathophysiological mechanisms of arterial remodeling.
Lessons learned from these relatively rare diseases may there-
fore ultimately provide insight in more common, multifactorial
cardiovascular diseases such as hypertension, diabetes mellitus,
and chronic kidney disease as well as in normal vascular aging.
GENERAL FEATURES OF ARTERIAL REMODELING
Arterial remodeling is thought to reflect adaptation of the ves-
sel wall to mechanical and hemodynamic stimuli (Nichols and
O’Rourke, 2005). Arterial remodeling is characterized by alter-
ations in the structure and function of the vascular wall and
can be divided into atherosclerosis and arteriosclerosis. Whereas
atherosclerosis is characterized by a focal inflammatory process
in the intima initiated by accumulation of lipids in plaques, arte-
riosclerosis is a more diffusely localized alteration of the medial
arterial vascular wall (Libby, 2002). Arteriosclerosis is associ-
ated with aging and generalized cardiovascular, metabolic, or
inflammatory disease. Macroscopically, different types of arte-
rial remodeling can be distinguished, depending on the type
and localization of the vessel (Figure 1) (Mulvany et al., 1996).
Arterial remodeling can be either inward or outward and can be
hypertrophic (thickening of the vascular wall), eutrophic (con-
stant wall thickness), or hypotrophic (thinning of the vascular
wall) (Mulvany et al., 1996). Changes observed in arteriosclerotic
arterial remodeling aremainly seen in large central elastic arteries.
They are characterized by increased vessel diameter and thickened
intimal and medial layers of the vascular wall (outward hyper-
trophic remodeling) (O’Rourke and Hashimoto, 2007). On the
other hand, remodeling of muscular peripheral vessels is more
often inwardly eutrophic or hypertrophic, probably reflecting
sustained vasoconstriction of vessels (Mulvany, 2008).
Thickening of the arterial wall is caused by intimal hyperplasia,
medial hypertrophy and hyperplasia of VSMCs, and deposition
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FIGURE 1 | Types of vascular remodeling. Adapted from Mulvany et al.
(1996). Different types of arterial remodeling can be distinguished:
hypotrophic (left column), eutrophic (center column) and hypertrophic
(right column). In addition remodeling can be either inward or outward.
Hypotrophic remodeling results in a relative thinner wall and a lower
wall-to-lumen ratio. Conversely hypertrophic remodeling is characterized by
thickening of the vascular wall due to cellular hyperplasia and/or
hypertrophy or deposition of extracellular matrix material and results in
increased wall-to-lumen ratio. When the diameter of the vessel changes but
the wall-to-lumen ratio remains the same it is called eutrophic remodeling.
All types of arterial remodeling can occur in cardiovascular disease,
depending on the underlying pathophysiology (e.g., aneurysm or
hypertensive arterial stiffening) and arterial site (e.g., central elastic
arteries vs. peripheral resistance arteries).
of ECM material including minerals (Virmani et al., 1991; Safar
et al., 1998; Schwartz et al., 2000). The normal composition
and lay-out of ECM of the vascular wall is disrupted in arterial
remodeling. In the media of the normal arterial wall, elastic fibers
are arranged in parallel, concentric, fenestrated layers, alternating
with layers of VSMCs anchored to the elastic fibers and structural
fibers by glycoproteins and integrins (Dingemans et al., 2000;
Nichols and O’Rourke, 2005). These structures, termed elastic
lamellae, enable the vessel to expand and buffer the systolic blood
pressure pulse, while simultaneously maintaining structural sta-
bility. Elastic fibers provide passive elastic buffering, whereas
VSMCs dynamically redistribute tensile stress across fibers due to
their ability to contract and relax (Rachev and Hayashi, 1999).
With arterial remodeling the layered architecture of elastic lamel-
lae is lost as they become progressively fragmented and fibrotic
(Farand et al., 2007). At higher levels of blood pressure, vessels
dilate which results in increased tensile stress on the vascular wall,
in accordance with LaPlace’s Law of circumferential wall tension
(Nichols and O’Rourke, 2005). Thickening of the arterial wall
occurring with arterial remodeling reduces tensile stress. VSMCs
of adults do not synthesize new elastin but mainly non-elastic
collagen resulting in stiffening of the vascular wall (Greenwald,
2007). Closely related to the degradation of ECM, the deposi-
tion of calcium minerals further contributes to stiffening and
remodeling of vascular tissue (Blaha et al., 2009; Sekikawa et al.,
2012).
In addition to structural changes, endothelial function plays an
important role in arterial remodeling. Blood flow and shear stress
stimulate endothelial cells to produce nitric oxide (NO), which in
turn influences contraction and relaxation of VSMCs. Endothelial
function decreases with age and endothelial dysfunction is com-
mon in many cardiovascular diseases. Moreover, in response to
pathological conditions, such as altered shear stress or inflam-
mation, endothelial cells produce cytokines and growth factors
that influence the homeostasis of the vascular wall (Csiszar et al.,
2009; Urschel et al., 2012). Endothelial cells produce transforming
growth factor-beta (TGF-β) and bone morphogenetic proteins
(BMPs) which stimulate VSMCs and vascular pericytes to pro-
liferate, to differentiate and to deposit ECM matrix (discussed in
more detail below) (Simionescu et al., 2005; Boström et al., 2011).
PATHOGENESIS OF ARTERIAL REMODELING
Arterial remodeling is driven by numerous, highly regulated and
interrelated processes. Processes that are of particular importance
as they are central in arterial remodeling include: (1) VSMC
proliferation and differentiation, (2) degradation and fracture of
elastin fibers, and (3) calcification and deposition of ECM mate-
rial (Figure 2). Genetic diseases with a phenotype resembling
vascular disease all affect one or several of these key processes
and may thus provide more insight in the mechanisms of vascular
disease (Figure 3).
VASCULAR SMOOTH MUSCLE CELL PROLIFERATION AND
DIFFERENTIATION
VSMCs are key regulators of vascular tone and health and insight
into their function is of utmost importance for our understanding
of the causes of arterial remodeling. In normal arteries, VSMCs
in the tunica media regulate vessel tone and diameter in order to
maintain hemodynamic balance (Alexander and Owens, 2012).
To fulfill this regulatory function, VSMCs need to have a con-
tractile phenotype. Contractile VSMCs are characterized by a
number of phenotype-specific marker proteins such as smooth
muscle 22-alpha (SM22α), alpha-smooth muscle actin (αSMa),
and smoothelin (Iyemere et al., 2006; Eys et al., 2007). Although
the majority of VSMCs in the vascular wall display a contractile
phenotype, studies have shown that a specific subset of medial
VSMCs has the ability to differentiate into a synthetic phenotype
which can be further subdivided into a migratory-proliferative
phenotype, a secretory phenotype or an osteogenic phenotype
(Gerthoffer, 2007). Phenotypic flexibility of VSMCs is necessary
to deal with the varying conditions of vascular tissue. Stress sig-
nals switch gene expression that will modulate VSMC phenotype
to adapt. This process of differentiation is termed phenotype
switching and is considered to be a key mechanism in arterial
remodeling (Iyemere et al., 2006; Alexander and Owens, 2012).
Phenotype switching occurs in response to vascular injury
or stress and is characterized by reduced expression of genes
which are specific for contractile VSMCs and cellular morphol-
ogy (Alexander and Owens, 2012). Although the precise mech-
anisms are still not fully understood, many different stimuli
have been identified, some of which are summarized in Table 1
Frontiers in Genetics | Systems Biology December 2012 | Volume 3 | Article 290 | 2
van Varik et al. Mechanisms of arterial remodeling
FIGURE 2 | Pathophysiological mechanisms of arterial remodeling.
Cross sectional schematic view of the arterial wall. (A) Normal
situation. (B) Arterial remodeling. Arterial remodeling is characterized
by thickening of the wall. Elastic fiber degradation, extracellular matrix
calcification and collagen deposition lead to adaptation of the vascular
wall. Abbreviations: TGF-β, transforming growth factor-beta; IL-1,
interleukin 1; MMP, matrix metalloproteinases; VSMC, vascular smooth
muscle cell.
FIGURE 3 | Pathophysiological pathways leading to arterial remodeling in genetic and cardiovascular disease. Abbreviations: PXE, pseudoxanthoma
elasticum; MMP, matrix metalloproteinases; VSMC, vascular smooth muscle cell; GGCX, gamma glutamyl transferase.
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Table 1 | Stimuli for vascular smooth muscle phenotype switching.
Inflammation
Oxidative stress
Hemodynamic shear stress
Mechanical stretch
Advanced glycation end products (AGE)
Increased calcium-phosphate product
SYSTEMIC HORMONAL
Angiotensin II (Ang II)
Aldosterone
PARACRINE STIMULI
Transforming growth factor-β (TGF-β)
Fibroblast growth factor (FGF)
Endothelial growth factor (EGF)
Platelet derived growth factor (PDGF)
Matrix metalloproteinases (MMP)
(Alexander and Owens, 2012). Migratory stimuli, for instance,
alter the cytoskeleton of VSMCs. As a consequence, cell adhesion
molecules are detached from the ECM and surrounding vascular
cells. Lamellipodia protrude from the leading edge of the cell due
to actin polymerization, enabling it to move through the ECM
toward a chemotactic stimulus (Willis et al., 2004). This migra-
tion contributes to intimal VSMC proliferation and hyperplasia,
which is an important cause of arterial wall thickening.
Synthetic VSMCs produce elastolytic enzymes (matrix met-
alloproteinases; MMPs), which facilitate migration by detaching
cells from the basement membrane and ECM. Indeed, upregu-
lation of MMPs coincides with the migration of VSMCs (Willis
et al., 2004). A genetic disorder that is associated with VSMC
phenotype switching is Marfan’s disease. It is characterized by
abnormal synthesis and function of elastic fibers (Kielty, 2006).
Patients with Marfan’s disease suffer from abnormal growth,
skeletal disorders, ocular problems and increased tendency to
develop aneurysms. The gene defect underlying Marfan’s disease
is a mutation of the fibrillin-1 (FBN-1) gene, which encodes the
glycoprotein FBN-1. FBN-1 is essential for maintaining struc-
tural stability of elastic fibers, as well as attaching VSMCs to the
elastic fibers (Bunton et al., 2001). Because of defective synthe-
sis, elastic fibers are prone to early mechanical fragmentation
and therefore disruption of elastic laminae. However, additional
studies on the pathophysiological mechanisms in Marfan’s dis-
ease showed that, preceding elastic fiber degradation, impaired
binding of VSMCs-induced differentiation into a synthetic pro-
teolytic phenotype (Galis et al., 1994; Bunton et al., 2001; Galis
and Khatri, 2002). The resulting production of MMPs dam-
ages the already weakened vascular wall (Pratt and Curci, 2010).
These patho-mechanistic changes in Marfan’s disease help to
understand underlying mechanisms leading to general vascular
disease. Indeed, Goodall et al. showed that VSMCs from infe-
rior mesenteric veins of patients with aortic aneurysms display
increased MMP-2 production and an increased number of migra-
tory VSMCs (Goodall et al., 2002). Bendeck et al. demonstrated
that inhibition of MMP activity inhibited VSMC migration in
rats (Bendeck et al., 1996). Moreover, VSMCs are important
for atherosclerotic plaque stability. VSMCs and myofibroblasts
in the fibrous cap provide stability to atherosclerotic plaques
if they deposit collagen. On the contrary, if a significant part
of these VSMCs display a proteolytic phenotype, degradation
of fibrous cap material may facilitate plaque rupture (Johnson,
2007). Therefore, the role of VSMCs in maintaining atheroscle-
rotic plaque stability largely depends on VSMCphenotype, stress-
ing out the importance to find therapeutic agents that are able to
modify the VSMC phenotype (Orr et al., 2010).
Osteogenic VSMC phenotype
Under specific stimuli such as sustained high extracellular levels
of calcium and phosphate or in the absence of inhibitors of calci-
fication, VSMCs can differentiate into an osteogenic phenotype
in which VSMCs acquire features usually observed in chon-
drocytes and osteoblasts (Shanahan et al., 1994; Iyemere et al.,
2006). Osteogenic VSMCs are characterized by down regulation
of mineralization inhibitory proteins, upregulation of alkaline
phosphatase and release of matrix vesicles (MVs) (Shanahan
et al., 2011). In vitro, culturing VSMCs with elevated phosphate
concentrations results in up-regulation of osteogenic markers
(Runx2, osterix, and alkaline phosphatase) and down-regulation
of VSMC lineage markers (SMa actin, SM22a) (Shanahan et al.,
2011). Downstream, bone morphogenetic protein-2 (BMP-2)
induces an osteogenic differentiation of VSMCs. BMP-2 has
been shown to be expressed in human atherosclerotic lesions
(Boström et al., 1993). The phenotypic switch of VSMCs to
chondrocyte- and osteoblast-like cells by BMP-2 is limited by cal-
cification inhibitory proteins such as matrix Gla-protein (MGP).
In MGP knock-out mice, the absence of MGP results in heavily
calcified elastic fibers, and loss of VSMCs which are differenti-
ated into chondrocytic VSMCs (Luo et al., 1997). Additionally,
MGP deficiency in VSMCs results in decreased smooth muscle
markers which is accompanied by an up-regulated expression
of the bone-specific transcription factor cbf1a/Runx2 and the
osteogenic protein osteopontin (Speer et al., 2002). The ability of
MGP to keep VSMCs in the contractile phenotype may be accom-
plished by binding BMP-2 (Wallin et al., 2000; Zebboudj et al.,
2003).
Tanimura and co-workers were the first to report an associa-
tion between small membrane encapsulated particles, MVs, and
vascular calcification (Tanimura et al., 1983). Vesicular structures
have been found in both intimal and medial layers and were likely
derived from VSMCs (Kim, 1976; Bennett et al., 1995; Hsu and
Camacho, 1999). The release of vesicle bodies from VSMCs was
first described as a rescue mechanism against calcium overload
trying to prevent apoptosis of VSMCs (Fleckenstein-Grün et al.,
1992). VSMC-derived MVs have been identified in human arter-
ies in association with atherosclerosis and hypertension (Kim,
1976; Kockx et al., 1998). In vitro, MV from VSMCs form the
nidus for calcification (Shanahan et al., 1999).
DEGRADATION AND FRACTURE OF ELASTIN FIBERS
Elastin
Elastic fibers consist of polymers of tropoelastin cross-linked to
fibrillin-rich microfibrils. In the vasculature, elastin is mainly
produced during the fetal and neonatal period by (secretory)
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VSMCs. Above we discussed the importance of elastin for
maintaining arterial wall stability and VSMC homeostasis in
Marfan’s Disease. Additionally, elastin is also an important nidus
for calcification. This is illustrated in PXE disease and its accom-
panying clinical features. PXE is characterized by extensive calcifi-
cation that mainly occurs along elastic fibers. Although cutaneous
manifestations are primarily of cosmetic concern, presence of
characteristic skin lesions signifies risk for development of vascu-
lar calcification with considerable morbidity and occasional early
mortality (Uitto et al., 2010).
Even in the absence of diseases which directly affect elastin
structure and function, similar processes can be observed in
vascular aging and aortic stiffening (Smith et al., 2012). The ques-
tion remains, what causes disruption of elastic fibers associated
with aging? Initially, it was hypothesized that elastin degrada-
tion was predominantly the result of material fatigue caused by
cyclic stretching of elastic fibers with every heart beat (O’Rourke,
1976; Nichols and O’Rourke, 2005). Diseases such as (systolic)
hypertension would accelerate this process, since increased pulse
pressure (PP) exerts greater tensile stress on the vascular wall and
increased stretch on fibers. In support of this hypothesis, struc-
tural alterations in elastin have been demonstrated to be inversely
associated with total number of heart beat cycles in vitro (Avolio
et al., 1998). However, there are no in vivo studies supporting
mechanical fragmentation of elastin.
CALCIFICATION AND DEPOSITION OF ECM MATERIAL
Both VSMC phenotype switching and ECM degradation result
in enhanced and accelerated vascular calcification. Initially, vas-
cular calcification was regarded as passive mineral deposition.
However, this view has been abandoned since overwhelming
evidence exists that vascular calcification actually is a highly reg-
ulated process. Soft tissue calcification is thought to result from
an imbalance between calcification-promoting and -inhibiting
factors (Table 2). Calcification is the hallmark of patients with
genetic diseases like Keutel’s syndrome, PXE, and PXE-like
Table 2 | Calcification regulating factors.
FACTORS PROMOTING CALCIFICATION
Bone morphogenetic protein 2 (BMP-2)
↑ Calcium-phosphate product
Tumor Necrosis Factor α (TNF-α)
Interleukin 6 (IL-6)
Receptor activator of nuclear factor κB (RANK) ligand (RANKL)
Insulin-like growth factor I (IGF-I)
Insulin
↑ Glucose
↑ Parathyroid hormone
Matrix metalloproteinases (MMP)
Elastin degradation
Hydroxyapatite crystals
FACTORS INHIBITING CALCIFICATION
Fetuin-A
Matrix gla protein (MGP)
Osteoprotegerin (OPG)
syndrome (Ziereisen et al., 1993; Munroe et al., 1999; Vanakker
et al., 2007; Rutsch et al., 2011). Keutel’s syndrome is caused by
a mutation in the gene encoding MGP, which is considered to be
the most important inhibitor of vascular calcification. MGP is a
14 kD protein which requires vitamin K-dependent carboxylation
to become biologically active. Clinically, lessons learned from the
mechanisms underlying Keutel’s disease can help understanding
vitamin K-antagonist-induced vascular calcifications (discussed
below) (Rennenberg et al., 2010;Weijs et al., 2011; Schurgers et al.,
2012).
In PXE, the underlying genetic defect is a loss-of-function
mutation of the abcc6 gene. This gene encodes a transmembrane
transporter protein (Multi Drug Resistant Protein 6; MDRP-6).
The substrate of the MDRP-6 is not known, and the exact mech-
anisms by which this mutation leads to elastin calcification are
not yet fully understood. Recent studies have pointed toward cal-
cification being stimulated by phenotype switching of VSMCs,
oxidative stress, and interference with carboxylation of MGP
(Pasquali-Ronchetti et al., 2006; Garcia-Fernandez et al., 2008;
Boraldi et al., 2009; Li et al., 2009b; Rutsch et al., 2011). Similarly,
in PXE-like syndrome a mutation in the γ-glutamylcarboxylase
(GGCX) gene causes elastic fiber calcification as is observed in
vitamin K-antagonist-induced vascular calcification (Gheduzzi
et al., 2007; Vanakker et al., 2007; Rennenberg et al., 2010; Weijs
et al., 2011; Schurgers et al., 2012). The GGCX mutation is
associated with increased bleeding tendency due to impairment
of vitamin K-dependent coagulation factors (Vanakker et al.,
2007; Li et al., 2009a). This has led to the concept that vitamin
K-dependent proteins are of importance in inhibiting vascular
elastin calcification. The GGCX mutation results in decreased
activity of MGP and subsequently an impaired inhibitory poten-
tial for calcification, similar to the situation in Keutel’s syndrome
in which MGP is absent (Schurgers et al., 2008; Vanakker et al.,
2010). In a similar manner, treatment with vitamin K-antagonists
may also induce an increased tendency for calcification (Figure 2)
(Price et al., 1998; Schurgers et al., 2007; Rennenberg et al.,
2010; Chatrou et al., 2012). Since vitamin K-antagonists work by
inhibiting the Vitamin K cycle and by reducing carboxylation of
MGP, these findings confirm the important central role of MGP
in the regulation of calcification. Therefore, it is highly probable
that in these diseases, MGP also plays an important regulatory
role in calcification (Shanahan et al., 1999; Schurgers et al., 2007).
CLINICAL ASPECTS OF ARTERIAL REMODELING
Since the normal function of vessels is to maintain adequate
perfusion of organs and tissues and to buffer oscillating blood
pressures, arterial remodeling results in changes in this func-
tion. At first, these are compensatory (i.e., reducing wall tension).
However, in later stages these compensatory mechanisms become
detrimental and initiate a vicious cycle of pathophysiological
aberrations.
ARTERIAL REMODELING, ARTERIAL STIFFNESS AND DAMAGING
HEMODYNAMICS
Fragmentation of the elastic lamina, hyperplasia and hypertro-
phy of VSMC, loss of contractility of VSMC, deposition of
collagen, and arterial calcification lead to stiffening of arteries.
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Many studies have shown that arterial stiffness, which is clinically
measured as the carotid-femoral pulse wave velocity (cfPWV), is
independently associated with cardiovascular risk and mortality
(Laurent et al., 2001, 2012; Mitchell et al., 2010; Vlachopoulos
et al., 2010). In addition, arterial stiffness is independently asso-
ciated with, and predictive of target organ damage of the heart,
kidneys, and brain (Laurent and Boutouyrie, 2005). Arterial stiff-
ness reflects the degree of remodeling in large arteries and is
used as a parameter for cardiovascular risk stratification next to
traditional cardiovascular risk factors (Nurnberger et al., 2002).
The mechanism linking arterial stiffness to an adverse outcome is
thought to involve a pathological hemodynamic profile in large,
central arteries such as the aorta (Mitchell, 2009). This patholog-
ical hemodynamic pattern consists of an increased systolic blood
pressure (SBP; i.e., systolic hypertension) and decreased diastolic
blood pressure (DBP) resulting in an increased PP. The pressure
waveform in the aorta is composed of a forward traveling wave
generated by contraction of the left ventricle of the heart, and a
backwards traveling wave generated by reflection from peripheral
arteries (Figure 4A). This reflected wave is generated at vascular
bifurcations and at sites where the elastic conduit arteries tran-
sition into muscular resistance arteries (Mitchell, 2004). At this
site the difference in impedance of the vascular wall causes the
forward traveling wave to be reflected. The shape of the aortic
pressure waveform is largely determined by timing and speed
with which the pulse wave propagates through the arteries. With
arterial stiffening the speed of both the forward and backward
traveling wave is increased. Remodeling of arteries causes an
earlier wave reflection. As a result of different timing of both
waves, the forward traveling wave and the reflected wave are sum-
mated, leading to an augmented systolic peak and a relatively
low DBP (Figure 4B), generating a highly pulsatile flow in aorta
and branching arteries. It is this blood pressure pulsatility that is
thought to have damaging effects on sensitive target organs as well
as on vascular function, and to contribute to the vicious cycle of
arterial remodeling.
High blood pressure pulsatility leads to increased mechanical
vascular wall stress. With high central PP, the amplitude in which
the arterial wall expands and contracts with each consecutive
heartbeat is increased. This leads to higher stretch on elastic and
collagen fibers in the arterial wall and this in turn may contribute
to material fatigue, fracture, and degradation. Additionally, cyclic
stretching of VSMC has been demonstrated to stimulate phe-
notype switching and arterial remodeling (Williams, 1998).
Secondly, pathological blood pressure pulsatility adversely affects
endothelial function since structure and function of the endothe-
lium are modulated by hemodynamic forces (Gimbrone and
García-Cardeña, 2012). In hypertensive patients, a high pulse-
pressure is associated with endothelial dysfunction, which can be
measured as the vasodilator response to acetylcholine (Ceravolo
et al., 2003). In the normal situation, a laminar blood flow pat-
tern and cyclic shear stress maintain proper endothelial function
such as: NO-mediated regulation of vascular tone, maintain-
ing a non-thrombotic and non-inflammatory state, preserving
ECM metabolism, and regulating vascular permeability (Vita
and Mitchell, 2003; Gimbrone and García-Cardeña, 2012). In
arteries with remodeling, blood flow becomes increasingly oscil-
latory with peaked systolic flows as well as stasis and even flow
reversal during diastole (Domanski et al., 1999; Mitchell, 2004).
The ensuing turbulent flow and locally altered shear stress pat-
terns cause endothelial dysfunction, which is characterized by
impaired NO synthesis and upregulation of pro-inflammatory
and pro-atherogenic factors, increased oxidative stress, as well as
vasoconstriction (Keulenaer et al., 1998; Blackman et al., 2002;
Gimbrone and García-Cardeña, 2012). In addition, altered flow
and increased pressure pulsatility have been shown to activate the
endothelium and induce production of osteogenic factors such as
BMP-2 and BMP-4 (Qiu and Tarbell, 2000; Sorescu et al., 2003;
FIGURE 4 | Hemodynamic changes in arterial stiffening. (A) Aortic blood
pressure waveform of a healthy, normotensive person. The forwards traveling
wave precedes the (backwards traveling) reflected wave. (B) Aortic pressure
waveform of a person with arterial stiffness. Due to increased pulse wave
velocity, the forward traveling wave and reflected wave are summated
leading to augmented pulse pressure.
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Boström et al., 2011). Indeed, BMP-2 transgenic apoE−/− mice
display increased calcification of atheromatous lesions, whereas
MGP transgenic apoE−/− mice have less atherosclerotic miner-
alization, suggesting a key role for MGP in suppressing BMP-2-
induced vascular mineralization (Nakagawa et al., 2010; Yao et al.,
2010).
Arterial stiffness and endothelial function not only stimu-
late the development of atherosclerotic plaques but also further
promotes arterial media remodeling. In this way, arterial stiff-
ness may explain the interrelationship of arteriosclerosis and
atherosclerosis.
Finally, the pathological hemodynamic patterns due to arte-
rial stiffness lead to damage of susceptible organs such as kidneys,
brain, and heart. It has been established that arterial stiffness and
chronic kidney disease are closely interrelated (Safar et al., 2004).
Patients with primary kidney disease have accelerated arterial
remodeling and calcification due to altered homeostasis of cal-
cium and phosphate, high degrees of inflammation and oxidative
stress, uremia, altered cholesterol metabolism, and an activated
renin-angiotensin system (RAS) (Safar et al., 2004). Conversely,
increased arterial stiffness and pressure pulsatility induce renal
damage (Verhave et al., 2005; Ford et al., 2010; Briet et al., 2011;
Chen et al., 2011). Blood pressure pulsatility has been put forward
to be able to cause renal damage. Although kidneys are normally
protected against high blood pressure by an effective autoregula-
tion, abnormal blood pressure pulsatility has been shown to blunt
the renal myogenic response (Bidani and Griffin, 2004; Bidani
et al., 2009; Hultström, 2012), exposing the vulnerable glomerular
microcirculation to damaging pressure oscillations (Safar et al.,
2012).
CALCIFICATION AS CARDIOVASCULAR RISK FACTOR AND POSSIBLE
THERAPEUTIC TARGET
In PXE, PXE-like syndrome as well as in Keutel’s syndrome,
arterial calcification is an important feature of the clinical phe-
notype. Besides these, arterial calcification is also observed in
more common disorders such as diabetes, hyperparathyroidism,
and chronic kidney disease as well as in vascular aging. In addi-
tion, vascular calcificationmay be induced by drugs that adversely
affect the regulatory balance between factors inducing or inhibit-
ing calcification. For instance, chronic treatment with vitamin
K-antagonists (such as warfarin) is associated with peripheral
artery calcification (Rennenberg et al., 2010). Calcification occurs
in both arteriosclerosis and atherosclerosis. Aortic medial calci-
fication has been demonstrated to contribute to arterial stiffness
in different populations (Odink et al., 2008; Cecelja et al., 2011;
Sekikawa et al., 2012). Moreover, the presence of aortic cal-
cification is predictive of coronary artery disease (Jang et al.,
2012). Calcification of coronary arteries predominantly reflects
atherosclerosis and can be measured and quantified by com-
puted tomography (CT) using the calcium-score. The calcium
score (expressed as Agatston units) has been used as a sensitive
tool for risk stratification and decision-making regarding coro-
nary revascularization and diagnostic angiography. A negative
calcium score indicates that the presence of atherosclerotic plaque
is very unlikely, whereas a high calcium score is associated with
significant cardiovascular risk (Budoff et al., 2006). The impor-
tance of calcification with respect to cardiovascular outcome is
further stressed by the fact that rapid annual progression of the
calcium score is independently associated with outcome (Raggi
et al., 2004). For this reason, the calcification process may become
an important therapeutic target. The challenge is that an interven-
tion should be aimed at a modifiable factor in the pathophysio-
logical process. As can be learned from PXE, PXE-like syndrome
and Keutel’s syndrome, MGP and the vitamin K cycle are among
the most important known regulators of calcification and VSMC
phenotype switching. As described above, MGP requires vita-
min Kmediated carboxylation to be biologically active. Therefore,
treatment with vitamin K would theoretically inhibit or possibly
reverse arterial calcification and slow down the development of
arterial stiffness. Indeed, our group demonstrated that calcifica-
tion could be reversed in rats that had extensive calcification due
to warfarin treatment, by subsequently administering vitamin K
(Schurgers et al., 2007). In humans, the 3-year daily supplemen-
tation of 500 mcg vitamin K on top of a multi-vitamin resulted in
hold on progression of vascular calcification (Shea et al., 2009) In
the observational Rotterdam study, high dietary intake of vitamin
K was associated with better cardiovascular outcome and reduced
coronary artery calcification (Geleijnse et al., 2004; Gast et al.,
2009). Also, in post-menopausal women, treatment with vita-
min K resulted in improved markers of vascular stiffness (Braam
et al., 2003). Furthermore, a recent study by Westenfeld et al.
showed that vitamin K2 supplementation reduced plasma lev-
els of inactive, undercarboxylated MGP (Westenfeld et al., 2012).
Since vitamin K has no reported adverse side effects, it might be
a promising treatment for calcification. Clinical trials investigat-
ing the effects of vitamin K supplementation on calcification and
arterial remodeling are currently in progress.
ARTERIAL REMODELING AS POTENTIAL THERAPEUTIC TARGET
In addition to calcification, other pathophysiological pathways of
arterial remodeling such as arterial stiffening, fibrosis, or elastin
degradation may also be potential candidates for intervention.
However, finding suitable, modifiable candidates has proven to be
a challenge. Although most existing antihypertensive drugs may
reduce arterial stiffness to some extent, it is difficult to determine
whether this effect is mainly due to blood pressure reduction or
represents a true effect on ECM remodeling (Boutouyrie et al.,
2011). Since the RAS plays an important pro-fibrotic role in arte-
rial remodeling it has been suggested that beneficial effects of
RAS antagonists are (partly) due to their anti-fibrotic action,
independent of their effects on blood pressure. Indeed, Tropeano
et al. showed that treatment with 8mg perindopril was associ-
ated with lower carotid stiffness independently of the effects on
blood pressure, whereas a dose of 4mg did not have such an effect
(Tropeano et al., 2006). Similar blood-pressure-independent de-
stiffening effects have been reported for selective aldosterone
antagonists such as eplerenone (White et al., 2003), supporting
possible effects of RAS system inhibition on ECM remodeling.
Especially in diabetes, advanced glycation end-products (AGE)
contribute to arterial stiffness by creating cross-links between
elastic and collagen fibers. Therefore, the AGE crosslink-breaker
alagebrium has received attention as potential de-stiffening drug
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(Zieman et al., 2007). This α-Aminoguadine compound
improved aortic stiffness and improved peripheral arterial
endothelial function in hypertensive patients, independently of
blood pressure (Kass et al., 2001; Zieman et al., 2007). However,
further research is required to properly assess the effects and
safety of this class of drugs.
CONCLUSION AND FUTURE PERSPECTIVES
Studying genetic diseases such as PXE, PXE-like syndrome,
Keutel’s syndrome and Marfan’s disease increase our knowl-
edge about pathophysiological mechanisms underlying arte-
rial remodeling (summarized in Figures 2 and 3). Single gene
defects of these specific diseases affect major regulatory path-
ways such as VSMC phenotype switching, matrix degradation,
and calcification that are also involved in common cardiovas-
cular disease and aging. Lessons learned from PXE, PXE-like
syndrome and Keutel’s syndrome have given attention to the
major calcification regulatory protein MGP and has provided a
possible new target for intervention. In this way, the continued
study of these relatively rare genetic diseases may ultimately pro-
vide us with potential new targets for therapeutic intervention
above and beyond traditional cardiovascular risk management
and treatment of risk factors. Conceivably, since VSMC pheno-
type switching has such an important regulatory role in arterial
remodeling, specifically targeting the direction of VSMC pheno-
type switching may prove to be promising. Ultimately, these novel
concepts learned from studying specific genetic diseases can be
applied to general cardiovascular medicine.
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